The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

The new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or every-other-month injections.

The Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that has been shown to act as ...

The US Food and Drug Administration (FDA) has approved a new shot to prevent HIV, offering a long-acting alternative to daily ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

WHO celebrates FDA's nod to injectable lenacapavir for HIV prevention, promising easier adherence with biannual doses.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across ...

Lenacapavir is an antiretroviral medicine that helps prevent 99.9 per cent of all HIV transmission, according to studies.

Although largely as expected by investors, BMO Capital says lenacapavir’s approval for prevention, now known as Yeztugo, marks “a major win for Gilead (GILD)” in driving meaningful growth in its ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...